SCHEMBL3561937

SCHEMBL3561937

N#C/C(=C\c1ccc(-n2ccc(C(F)(F)F)n2)cc1)C(=O)c1cccc(F)c1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.43
RAB9A P51151 6/20 0.43
NPSR1 Q6W5P4 3/20 0.43
HTT P42858 1/20 0.43
PAX8 Q06710 1/20 0.43
MAPT P10636 5/20 0.42
KMT2A Q03164 4/20 0.39
MEN1 O00255 3/20 0.39
POLB P06746 1/20 0.37
CES2 O00748 1/20 0.36
BCHE P06276 1/20 0.36
CES1 P23141 1/20 0.36
KDM4E B2RXH2 3/20 0.36
MAPK1 P28482 1/20 0.36
EGFR P00533 1/20 0.35
ERBB2 P04626 1/20 0.35
LMNA P02545 1/20 0.35
F10 P00742 1/20 0.35
ALDH1A1 P00352 2/20 0.34
PKM P14618 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3561939 1.00 NPC1 (0.43) NPC1RAB9ANPSR1HTTPAX8
SCHEMBL3558542 0.86 NPC1 (0.46) NPC1RAB9ANPSR1HTTPAX8
SCHEMBL3558540 0.86 NPC1 (0.46) NPC1RAB9ANPSR1HTTPAX8
SCHEMBL3557244 0.84 NPC1 (0.43) NPC1RAB9ANPSR1HTTPAX8
SCHEMBL3557246 0.84 NPC1 (0.43) NPC1RAB9ANPSR1HTTPAX8
SCHEMBL3554842 0.84 NPC1 (0.43) NPC1RAB9ANPSR1HTTPAX8
SCHEMBL3554839 0.84 NPC1 (0.43) NPC1RAB9ANPSR1HTTPAX8
SCHEMBL3562516 0.83 KMT2A (0.39) HTTMAPTKMT2AMEN1POLB
SCHEMBL3562519 0.83 KMT2A (0.39) HTTMAPTKMT2AMEN1POLB
SCHEMBL13404469 0.83 ORAI1 (0.43) NPC1RAB9AMAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705029-B2 Acrylonitrile derivatives for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2010-04-27 US disclosed
US-20070270478-A1 ACRYLONITRILE DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2007-11-22 US disclosed
US-7202232-B2 Acrylonitrile derivatives for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2007-04-10 US disclosed
US-20050272699-A1 Acrylonitrile derivatives for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. 2005-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272699-A1 Acrylonitrile derivatives for inflammation and immune-related uses IL1B, IL6, TLR4 NPC1 601/4885RAB9A 3946/4885NPSR1 1043/4885
US-20070270478-A1 ACRYLONITRILE DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES IL1B, IL6, TLR4 NPC1 601/4885RAB9A 3946/4885NPSR1 1043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.